Enovis Corporation logo

Enovis Corporation

ENOV

NYSEHealthcareMedical - Devices

Regular session

$26.325

+$0.265 · +1.02%

Aug 24, 10:32 AM ET

ENOV company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

50

Neutral

Sentiment

66

Bullish

Risk resilience

41

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Damien McDonald
Listed since
May 8, 2008
Employees
7,802

Market position

Day range

Current $26.325

52-week range

Current $26.325

Open
$26.28
Previous close
$26.06
Volume
44.01K
0.04× average
Average volume
1.15M
Average daily volume
Market cap
1.52B USD
Beta
1.45
Market reference 1
50-day average
$25.1914
+4.50% above average
200-day average
$25.095
+4.90% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.86B USD
P/E (TTM)
-1.36×
P/B (TTM)
1.03×
P/S (TTM)
0.66×
EV / EBITDA
-3.44×
Earnings yield
-78.29%
Free cash flow yield
1.32%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
57.43%
Operating margin
4.14%
Net margin
-47.97%
Return on equity
-79.51%
Return on assets
-30.89%
Return on invested capital
-0.57%

Financial health

Debt / equity
0.93×
Current ratio
2.02×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends71%26%-19%-64%Gross margin, FY2021: 54.53%Gross margin, FY2022: 55.62%Gross margin, FY2023: 58.04%Gross margin, FY2024: 56.02%Gross margin, FY2025: 59.84%Operating margin, FY2021: -4.40%Operating margin, FY2022: -4.55%Operating margin, FY2023: -3.85%Operating margin, FY2024: -36.81%Operating margin, FY2025: -0.84%Net margin, FY2021: 5.02%Net margin, FY2022: -0.85%Net margin, FY2023: -1.95%Net margin, FY2024: -39.17%Net margin, FY2025: -52.69%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 54.53%. Gross margin FY2022 55.62%. Gross margin FY2023 58.04%. Gross margin FY2024 56.02%. Gross margin FY2025 59.84%. Operating margin FY2021 -4.40%. Operating margin FY2022 -4.55%. Operating margin FY2023 -3.85%. Operating margin FY2024 -36.81%. Operating margin FY2025 -0.84%. Net margin FY2021 5.02%. Net margin FY2022 -0.85%. Net margin FY2023 -1.95%. Net margin FY2024 -39.17%. Net margin FY2025 -52.69%.

Income trends

Revenue

2.25B USD+6.66%

Operating income

−18.87M USD+97.57%

Net income

−1.18B USD-43.48%
Income trends across reported periods2.59B USD1.22B USD−154.69M USD−1.53B USDRevenue, FY2021: 1.43B USDRevenue, FY2022: 1.56B USDRevenue, FY2023: 1.71B USDRevenue, FY2024: 2.11B USDRevenue, FY2025: 2.25B USDOperating income, FY2021: −62.8M USDOperating income, FY2022: −71.18M USDOperating income, FY2023: −65.71M USDOperating income, FY2024: −775.72M USDOperating income, FY2025: −18.87M USDNet income, FY2021: 71.66M USDNet income, FY2022: −13.29M USDNet income, FY2023: −33.26M USDNet income, FY2024: −825.49M USDNet income, FY2025: −1.18B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.43B USD. Revenue FY2022 1.56B USD. Revenue FY2023 1.71B USD. Revenue FY2024 2.11B USD. Revenue FY2025 2.25B USD. Operating income FY2021 −62.8M USD. Operating income FY2022 −71.18M USD. Operating income FY2023 −65.71M USD. Operating income FY2024 −775.72M USD. Operating income FY2025 −18.87M USD. Net income FY2021 71.66M USD. Net income FY2022 −13.29M USD. Net income FY2023 −33.26M USD. Net income FY2024 −825.49M USD. Net income FY2025 −1.18B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue2.25B USD2.11B USD1.71B USD1.56B USD1.43B USD
Cost of goods sold902.79M USD926.87M USD716.42M USD693.72M USD648.51M USD
Gross profit1.35B USD1.18B USD990.78M USD869.38M USD777.68M USD
Research and development120.33M USD91.3M USD75.33M USD60.83M USD49.09M USD
Selling, general, and administrative1.07B USD939.36M USD830.31M USD772.91M USD665.78M USD
Operating expenses1.36B USD1.96B USD1.06B USD940.56M USD840.47M USD
Interest income200K USD
Interest expense34.82M USD57.1M USD19.75M USD24.95M USD29.11M USD
Depreciation and amortization294.38M USD284.8M USD217.11M USD219.71M USD262.92M USD
Operating income−18.87M USD−775.72M USD−65.71M USD−71.18M USD−62.8M USD
Net income−1.18B USD−825.49M USD−33.26M USD−13.29M USD71.66M USD

Company facts updated Aug 24, 2026.

ENOV peers

ETFs holding ENOV

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ENOV

research.disclaimer